Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
Author:
Benjamin M Segal,Cris S Constantinescu,Aparna Raychaudhuri,Lilianne Kim,Rosanne Fidelus-Gort,Lloyd H Kasper
Publication:
The Lancet Neurology
Copyright © 2008 Elsevier Ltd. All rights reserved.